A study led by Michela Gallagher of The Johns Hopkins University and published in the May 10 issue of the journal Neuron suggests a potential new therapeutic approach for improving memory and interrupting disease progression in patients with a form of cognitive impairment that often leads to full-blown Alzheimer’s disease.
Recent news from The Johns Hopkins University
This section contains regularly updated highlights of the news from around The Johns Hopkins University. Links to the complete news reports from the nine schools, the Applied Physics Laboratory and other centers and institutes are to the left, as are links to help news media contact the Johns Hopkins communications offices.
An existing anti-seizure drug improves memory and brain function in adults with a form of cognitive impairment that often leads to full-blown Alzheimer’s disease, according to a study led by neuroscientist Michela Gallagher of The Johns Hopkins University. The findings raise the possibility that doctors will someday be able to use the drug, levetiracetam, already approved for use in epilepsy patients, to slow the abnormal loss of brain function in some aging patients before their condition becomes Alzheimer’s.
Using a $1.3 million National Institutes of Health grant underwritten by the federal stimulus act, Krieger School psychologist Michela Gallagher and her team are about to embark on one of their most important studies yet: determining whether a medication commonly used to treat seizures can help improve memory and brain function in adults suffering from mild cognitive impairment, or MCI, a common precursor to full-blown Alzheimer’s disease.